LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Atvērts

SektorsVeselības aprūpe

160.23 0.91

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

159.54

Max

161.2

Galvenie mērījumi
By Trading Economics
Ienākumi	262M -15M
Pārdošana	1.6M 996M
EPS	2.06
Peļņas marža	-1.486
Darbinieki	18,300
EBITDA	-11M 187M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+28.12% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.3B 7.2B
Iepriekšējā atvēršanas cena	159.32
Iepriekšējā slēgšanas cena	160.23

Ziņu noskaņojums

By Acuity

50%

151 / 345 Rangs Healthcare

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. maijs 23:46 UTC

Tirgus saruna

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

2026. g. 24. maijs 23:45 UTC

Tirgus saruna

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

2026. g. 24. maijs 23:42 UTC

Tirgus saruna

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

2026. g. 24. maijs 23:34 UTC

Tirgus saruna

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

2026. g. 24. maijs 23:11 UTC

Tirgus saruna

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

2026. g. 24. maijs 22:26 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

2026. g. 24. maijs 22:25 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

2026. g. 24. maijs 22:25 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

2026. g. 24. maijs 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

2026. g. 24. maijs 22:24 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

2026. g. 24. maijs 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

2026. g. 24. maijs 22:23 UTC

Iegādes, apvienošanās, pārņemšana

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

2026. g. 24. maijs 22:11 UTC

Tirgus saruna

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

2026. g. 24. maijs 22:04 UTC

Tirgus saruna

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

2026. g. 23. maijs 08:20 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 23. maijs 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. maijs 21:10 UTC

Peļņas

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 22. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 22. maijs 19:47 UTC

Peļņas

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

2026. g. 22. maijs 19:17 UTC

Tirgus saruna

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

2026. g. 22. maijs 19:10 UTC

Tirgus saruna

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. maijs 18:54 UTC

Tirgus saruna

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

2026. g. 22. maijs 18:38 UTC

Tirgus saruna

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

2026. g. 22. maijs 18:35 UTC

Iegādes, apvienošanās, pārņemšana

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

2026. g. 22. maijs 18:09 UTC

Tirgus saruna

Centralized Crypto Lending Slows in 1Q -- Market Talk

2026. g. 22. maijs 17:58 UTC

Tirgus saruna

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

28.12% augšup

Prognoze 12 mēnešiem

Vidējais 205.38 USD 28.12%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

151 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.